skip to content
Antiviral drugs : from basic discovery through clinical trials Preview this item
ClosePreview this item
Checking...

Antiviral drugs : from basic discovery through clinical trials

Author: Wieslaw M Kazmierski
Publisher: Hoboken, N.J. : Wiley, ©2011.
Edition/Format:   Print book : EnglishView all editions and formats
Summary:

This book focuses on new small molecule approaches to combat viral infections. The chapters describe the discovery and development from bench through the clinic of relatively recently-approved  Read more...

Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Document Type: Book
All Authors / Contributors: Wieslaw M Kazmierski
ISBN: 9780470455630 0470455632 9780470929353 0470929359 9780470929346 0470929340 9780470934685 0470934689
OCLC Number: 642278776
Description: xiii, 438 pages, [16] pages of plates : illustrations (some color) ; 29 cm
Contents: Section 1. HIV Protease Inhibitors: Discovery and development of atazanavir --
Discovery and development of PL-100, a novel HIV-1 protease inhibitor --
Darunavir (Prezista, TMC114): from bench to clinic, improving treatment options for HIV-infected patients --
Discovery and development of tipranavir --
Section II. HIV Non-nucleoside Reverse Transcriptase Inhibitors: TMC278 (Rilpivirine): a next-generation NNRTI in phase III clinical development for treatment-naive patients --
Entravirine: from TMC125 to intelence: a treatment paradigm shift for HIV-infected patients --
Section III. HIV Nucleoside Reverse Transcriptase Inhibitors: Discovery and development of tenovir disoproxil fumarate --
Discovery and development of apricitabine --
Section IV. HIV Entry Inhibitors: Discovery and development of maraviroc and PF-232798: CCR5 antagonists for the treatment of HIV-1 infection --
Discovery of the CCR5 antagonist vicriviroc (Sch 417690/Sch-D) for the treatment of HIV-1 infection --
Discovery and development of HIV-1 entry inhibitors that target gp120 --
Section V. HIV Integrase Inhibitors: Discovery of MK-0536: a potential second-generation HIV-1 integrase strand transfer inhibitor with a high genetic barrier to mutation --
Discovery and development of HIV integrase inhibitor raltegravir --
Elvitegravir: a novel monoketo acid HIV-1 integrase strand transfer inhibitor. Section VI. Protease Inhibitors: Discovery and development of telaprevir --
Discovery and development of BILN 2061 and follow-up BI 201335 --
Intervention of Hepatitis C replication through NS3-4A, the protease inhibitor boceprevir --
Discovery and development of the HCV NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) --
Discovery and development of the HCV protease inhibitor TMC435 --
Section VII. HCV Polymerase Nucleoside Inhibitors: Discovery and clinical evaluation of the nucleoside analog balapiravir (R1626) for the treatment of HCV infection --
Discovery and development of PSI-6130/RG7128 --
Section VIII. Other HCV Inhibitors: Discovery of Cyclophilin inhibitor NIM811 as a novel therapeutic agent for HCV --
HCV viral entry inhibitors --
Discovery of the RSV inhibitor TMC353121 --
Discovery and development of orally active RSV fusion inhibitors --
Discovery and development of RSV604 --
Discovery and development of influenza virus sialidase inhibitor relenza --
Discovery and development of entecavir --
Benzimidazole ribonucleosides: novel drug candidates for the prevention and treatment of cytomegalovirus diseases.
Responsibility: edited by Wieslaw M. Kazmierski.

Reviews

Editorial reviews

Publisher Synopsis

"I very much enjoyed this book and learned greatly from it ... The book is a valuable resource for researchers working in the discovery and early development of antiviral agents, and also for those Read more...

 
User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/642278776> # Antiviral drugs : from basic discovery through clinical trials
    a schema:Book, schema:CreativeWork ;
   library:oclcnum "642278776" ;
   library:placeOfPublication <http://experiment.worldcat.org/entity/work/data/988789517#Place/hoboken_n_j> ; # Hoboken, N.J.
   library:placeOfPublication <http://id.loc.gov/vocabulary/countries/nju> ;
   schema:about <http://dewey.info/class/615.7924/e22/> ;
   schema:about <http://experiment.worldcat.org/entity/work/data/988789517#Topic/clinical_trials_as_topic> ; # Clinical Trials as Topic
   schema:about <http://experiment.worldcat.org/entity/work/data/988789517#Topic/antiviral_agents_therapeutic_use> ; # Antiviral Agents--therapeutic use
   schema:about <http://id.worldcat.org/fast/810869> ; # Antiviral agents
   schema:about <http://experiment.worldcat.org/entity/work/data/988789517#Topic/drug_evaluation> ; # Drug Evaluation
   schema:about <http://experiment.worldcat.org/entity/work/data/988789517#Topic/drug_discovery> ; # Drug Discovery
   schema:bookFormat bgn:PrintBook ;
   schema:contributor <http://viaf.org/viaf/6717664> ; # Wieslaw M. Kazmierski
   schema:copyrightYear "2011" ;
   schema:datePublished "2011" ;
   schema:description "Section 1. HIV Protease Inhibitors: Discovery and development of atazanavir -- Discovery and development of PL-100, a novel HIV-1 protease inhibitor -- Darunavir (Prezista, TMC114): from bench to clinic, improving treatment options for HIV-infected patients -- Discovery and development of tipranavir -- Section II. HIV Non-nucleoside Reverse Transcriptase Inhibitors: TMC278 (Rilpivirine): a next-generation NNRTI in phase III clinical development for treatment-naive patients -- Entravirine: from TMC125 to intelence: a treatment paradigm shift for HIV-infected patients -- Section III. HIV Nucleoside Reverse Transcriptase Inhibitors: Discovery and development of tenovir disoproxil fumarate -- Discovery and development of apricitabine -- Section IV. HIV Entry Inhibitors: Discovery and development of maraviroc and PF-232798: CCR5 antagonists for the treatment of HIV-1 infection -- Discovery of the CCR5 antagonist vicriviroc (Sch 417690/Sch-D) for the treatment of HIV-1 infection -- Discovery and development of HIV-1 entry inhibitors that target gp120 -- Section V. HIV Integrase Inhibitors: Discovery of MK-0536: a potential second-generation HIV-1 integrase strand transfer inhibitor with a high genetic barrier to mutation -- Discovery and development of HIV integrase inhibitor raltegravir -- Elvitegravir: a novel monoketo acid HIV-1 integrase strand transfer inhibitor."@en ;
   schema:description "Section VI. Protease Inhibitors: Discovery and development of telaprevir -- Discovery and development of BILN 2061 and follow-up BI 201335 -- Intervention of Hepatitis C replication through NS3-4A, the protease inhibitor boceprevir -- Discovery and development of the HCV NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) -- Discovery and development of the HCV protease inhibitor TMC435 -- Section VII. HCV Polymerase Nucleoside Inhibitors: Discovery and clinical evaluation of the nucleoside analog balapiravir (R1626) for the treatment of HCV infection -- Discovery and development of PSI-6130/RG7128 -- Section VIII. Other HCV Inhibitors: Discovery of Cyclophilin inhibitor NIM811 as a novel therapeutic agent for HCV -- HCV viral entry inhibitors -- Discovery of the RSV inhibitor TMC353121 -- Discovery and development of orally active RSV fusion inhibitors -- Discovery and development of RSV604 -- Discovery and development of influenza virus sialidase inhibitor relenza -- Discovery and development of entecavir -- Benzimidazole ribonucleosides: novel drug candidates for the prevention and treatment of cytomegalovirus diseases."@en ;
   schema:exampleOfWork <http://worldcat.org/entity/work/id/988789517> ;
   schema:inLanguage "en" ;
   schema:name "Antiviral drugs : from basic discovery through clinical trials"@en ;
   schema:productID "642278776" ;
   schema:publication <http://www.worldcat.org/title/-/oclc/642278776#PublicationEvent/hoboken_n_j_wiley_2011> ;
   schema:publisher <http://experiment.worldcat.org/entity/work/data/988789517#Agent/wiley> ; # Wiley
   schema:workExample <http://worldcat.org/isbn/9780470934685> ;
   schema:workExample <http://worldcat.org/isbn/9780470929353> ;
   schema:workExample <http://worldcat.org/isbn/9780470929346> ;
   schema:workExample <http://worldcat.org/isbn/9780470455630> ;
   wdrs:describedby <http://www.worldcat.org/title/-/oclc/642278776> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/988789517#Topic/antiviral_agents_therapeutic_use> # Antiviral Agents--therapeutic use
    a schema:Intangible ;
   schema:name "Antiviral Agents--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/988789517#Topic/clinical_trials_as_topic> # Clinical Trials as Topic
    a schema:Intangible ;
   schema:name "Clinical Trials as Topic"@en ;
    .

<http://id.worldcat.org/fast/810869> # Antiviral agents
    a schema:Intangible ;
   schema:name "Antiviral agents"@en ;
    .

<http://viaf.org/viaf/6717664> # Wieslaw M. Kazmierski
    a schema:Person ;
   schema:familyName "Kazmierski" ;
   schema:givenName "Wieslaw M." ;
   schema:name "Wieslaw M. Kazmierski" ;
    .

<http://worldcat.org/isbn/9780470455630>
    a schema:ProductModel ;
   schema:isbn "0470455632" ;
   schema:isbn "9780470455630" ;
    .

<http://worldcat.org/isbn/9780470929346>
    a schema:ProductModel ;
   schema:isbn "0470929340" ;
   schema:isbn "9780470929346" ;
    .

<http://worldcat.org/isbn/9780470929353>
    a schema:ProductModel ;
   schema:isbn "0470929359" ;
   schema:isbn "9780470929353" ;
    .

<http://worldcat.org/isbn/9780470934685>
    a schema:ProductModel ;
   schema:isbn "0470934689" ;
   schema:isbn "9780470934685" ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.